GN-HEARING
2.4.2020 10:41:08 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service. At a time when elderly, more vulnerable populations are advised to stay home, this innovative telehealth solution enables people, from the comfort and safety of their home, to connect with their hearing care professional for new hearing aids and care remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005306/en/
GN Hearing recognizes that COVID-19 may seriously affect people who use hearing aids due to stricter social distancing measures, ultimately affecting many people’s wellbeing and mental health. Telehealth services can make an important difference in helping people stay connected with loved ones and informed on rapidly changing events while staying at home. People do not have to sacrifice their hearing and can get the help they need to hear better.
With the launch of ReSound Assist Live, people can now have new hearing aids adjusted remotely by their hearing care professional via new at-home video consultations without physically going to a clinic. Additionally, in these difficult times, hearing care professionals can provide new hearing aids for those who have recently completed a hearing test. In collaboration with HearX, a digital health care company focused on mobile hearing screening, testing and video otoscopy, hearing care professionals in the US can also offer drive-through or at-home hearing tests and receive adjustments and counseling via ReSound Assist Live.
“At this critical time, GN Hearing is as committed as always to helping the hearing community where it’s most needed. For many people, staying in touch with loved ones on the phone and online demands great hearing abilities, so getting access to hearing care support is crucial, particularly for those in self-isolation when communicating is imperative for an individual’s wellbeing,” says Gitte Aabo, CEO and President of GN Hearing.
ReSound Assist Live is an update to ReSound Assist, which already lets people request and receive adjustments to their hearing aids remotely, but the new telehealth tech goes further, enabling live video consultations with hearing care professionals for support wherever they are. This allows in-person support over live video and remote fitting of hearing aids all via the ReSound Smart 3D™ app.
“We expect that the introduction of ReSound Assist Live will help more hearing aid users and their hearing care professionals connect via our innovative remote solutions that work for them, regardless of what’s going on in their lives, how much mobility they have during this difficult time, and in the future,” Gitte Aabo continues.
ReSound Assist Live is available on April 2, 2020 in the US, Canada, the U.K., Germany, Australia, New Zealand and Singapore, and globally from May 1. At-home and drive-through hearing tests will be offered shortly in the US.
- ENDS -
NOTES TO EDITORS
ReSound Assist Live enables individualized care from anywhere
New ReSound Assist Live is an extension of the existing ReSound Assist remote fine-tuning services and can be accessed via video call on the ReSound Smart 3D app. It is the only fitting software which offers comprehensive live video and remote adjustment options.
ReSound Assist already lets people request and receive adjustments to their hearing aids remotely, but ReSound Assist Live goes further, enabling them to speak directly to their hearing care professional over a live link. This means they can benefit from instant access to the highest level of care at a convenient time and place.
About ReSound
ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology. ReSound was the first hearing aid brand to be Made for iPhone and pioneered the development of 2.4 GHz wireless technology. The introduction of the sixth generation of this technology with ReSound LiNX QuattroTM demonstrates that ReSound is the absolute leader in the industry. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn , Facebook and Twitter .
© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom